Trial Profile
Real World Study To Assess Effectiveness and Safety of Vemurafenib As Monotherapy In Patients With Unresectable Or Metastatic Melanoma Using Data From MELBASE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Nov 2016
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 16 Nov 2016 New trial record
- 02 Nov 2016 Results of this study, presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.